Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab effects on arterial plaque inflammation in rheumatoid arthritis
NL-OMON41532Active, not recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Sep 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of adalimumab and methotrexate in rheumatoid arthritis (RA) (3 arms), sponsored by Jan van Breemen Institute. Primary endpoints: Baseline difference in arterial 18-FDG uptake between rheumatoid arthritis patients and controls and Change in arterial 18-FDG uptake after methotrexate or Humira. Started Sep 2011; status: active, not recruiting.
02
Drugs
adalimumabmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON41532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41532.